Akèy › Limfom Difize Gwo Selil B › Ohio › Cincinnati
Etid klinik pou Limfom Difize Gwo Selil B nan Cincinnati, OH
11 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Cincinnati (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi lwen
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Ap rekriteFaz 2/3
- Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood · 8 mi lwen
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- University of Cincinnati Medical Center ( Site 0156), Cincinnati
- Saint Elizabeth Medical Center Edgewood ( Site 0141), Edgewood · 8 mi lwen
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002), Cincinnati
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
- Oncology Hematology Care - Kenwood, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- University of Cincinnati Medical Center, Cincinnati
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Ap rekriteFaz 1
- University of Cincinnati, Cincinnati
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Ap rekriteFaz 1/2
- University of Cincinnati, Cincinnati
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Los Angeles, CA17 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Portland, OR15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Nashville, TN14 etid
- Dallas, TX13 etid
Lòt etid nan Cincinnati
- Kansè Poumon ki pa ti selil35 etid
- Kansè (tout kalite)28 etid
- Kansè nan tete25 etid
- Ensifizyans kadyak24 etid
- Kansè kolorektal21 etid
- Kansè Metastatik20 etid
- Leksemi mieloïd egi20 etid
- Kansè poumon19 etid
- Kansè ovè19 etid
- Obèsite19 etid
- Kansè pwostat18 etid
- Myelom Miltip17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.